ALNYLAM PHARMACEUTICALS, INC. Equity Method Investment, Summarized Financial Information, Noncurrent Liabilities (Deprecated 2020-01-31)
ALNYLAM PHARMACEUTICALS, INC. (ALNY) had Equity Method Investment, Summarized Financial Information, Noncurrent Liabilities (Deprecated 2020-01-31) of $15.32 million as of 2012-09-30, per its 10-Q filed 2012-11-05.
Discontinued › Notes
us-gaap:EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiabilities · last filed 2013-02-19
- 2012-09-30: Equity Method Investment, Summarized Financial Information, Noncurrent Liabilities (Deprecated 2020-01-31) $15.32M.
- 2012-06-30: Equity Method Investment, Summarized Financial Information, Noncurrent Liabilities (Deprecated 2020-01-31) $13.91M.
- 2011-12-31: Equity Method Investment, Summarized Financial Information, Noncurrent Liabilities (Deprecated 2020-01-31) $28.83M.
| Period end | Equity Method Investment, Summarized Financial Information, Noncurrent Liabilities (Deprecated 2020-01-31) |
|---|---|
| 2012-09-30 | $15.32M 10-Q · filed 2012-11-05 |
| 2012-06-30 | $13.91M 10-Q · filed 2012-08-08 |
| 2011-12-31 | $28.83M 10-K · filed 2013-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |